Armistice Capital, LLC Reports 4.99% Stake in Bluejay Diagnostics, Inc. (BJDX)

On May 15, 2026, Armistice Capital, LLC and its managing member, Steven Boyd, filed a Schedule 13G/A with the SEC, reporting a new ownership stake in Bluejay Diagnostics, Inc. (BJDX). As of the event date on March 31, 2026, the reporting persons beneficially own 51,061 shares of common stock, representing 4.99% of the company. This filing marks an increase from a previously reported 0.0% ownership position. Armistice Capital, LLC serves as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares. Under an Investment Management Agreement, Armistice Capital exercises shared voting and dispositive power over the securities. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. The reporting persons have certified that the securities are held without an activist intent.